Mr. Hull's career has spanned over thirty years as a corporate executive in the global healthcare and biotechnology industries, including the last fourteen years at Takeda Pharmaceuticals where he currently serves as the Vice President of Global Alliances. Mr. Hull has substantial experience in the pharmaceutical industry, with a focus on strategic partnerships and commercialization of prescription drugs.
Eric A. Adams, President & CEO of InMed, commented, "We are extremely pleased to have an individual of Mr. Hull's caliber and reputation within the pharmaceutical community on our Board of Directors. His impressive track record in sales, marketing and R&D partnership formation and execution, together with his extensive network within the biopharma community will be significant contributions to InMed as we seek to unlock the value of the Company's diverse assets."
"This is an exciting time for InMed and I look forward to working with the company's executive team and other Board members to help fulfill the company's mission to develop novel therapies to improve the quality of life for patients." said Mr. Hull.
Additionally, InMed announces it has accepted the resignation of Chris Bogart and Sazzad Hossain as Directors of the Company, effective today. The Board wishes to thank Mr. Bogart and Dr. Hossain for their efforts on the Board and both individuals will continue their current roles as senior executives at InMed.
InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed's proprietary in silico drug/disease targeting platform, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com
Cautionary Note Regarding Forward-Looking Information
Forward Looking Statements
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
Additionally, there are known and unknown risk factors which could cause InMed Pharmaceuticals actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed Pharmaceuticals disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
SOURCE InMed Pharmaceuticals Inc.